{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:17:08Z","timestamp":1791303428446,"version":"4.1.0"},"reference-count":168,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Osteoporosis is an unavoidable public health problem in an aging or aged society. Anti-resorptive agents (calcitonin, estrogen, and selective estrogen-receptor modulators, bisphosphonates, anti-receptor activator of nuclear factor \u03baB ligand antibody along with calcium and vitamin D supplementations) and anabolic agents (parathyroid hormone and related peptide analogs, sclerostin inhibitors) have major roles in current treatment regimens and are used alone or in combination based on the pathological condition. Recent advancements in the molecular understanding of bone metabolism and in bioengineering will open the door to future treatment paradigms for osteoporosis, including antibody agents, stem cells, and gene therapies. This review provides an overview of the molecular mechanisms, clinical evidence, and potential adverse effects of drugs that are currently used or under development for the treatment of osteoporosis to aid clinicians in deciding how to select the best treatment option.<\/jats:p>","DOI":"10.3390\/ijms20102557","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T11:20:46Z","timestamp":1558696846000},"page":"2557","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-8854","authenticated-orcid":false,"given":"Yuichiro","family":"Ukon","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-1919","authenticated-orcid":false,"given":"Takahiro","family":"Makino","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsukazaki","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tateiwa","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-2997","authenticated-orcid":false,"given":"Takashi","family":"Kaito","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(1993). Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med., 94, 646\u2013650.","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"ref_2","unstructured":"(2019, March 22). Prevention and management of osteoporosis. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/42841."},{"key":"ref_3","unstructured":"(2019, March 22). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/39142."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.1208859","article-title":"The outlook for population growth","volume":"333","author":"Lee","year":"2011","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis international","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1172\/JCI27071","article-title":"Pathogenesis of osteoporosis: Concepts, conflicts, and prospects","volume":"115","author":"Raisz","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/jbmr.2240","article-title":"Dlx5 and mef2 regulate a novel runx2 enhancer for osteoblast-specific expression","volume":"29","author":"Kawane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1002\/jcb.23287","article-title":"Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation","volume":"112","author":"Lin","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nature756","article-title":"Kremen proteins are Dickkopf receptors that regulate Wnt\/beta-catenin signalling","volume":"417","author":"Mao","year":"2002","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4248\/BR201301003","article-title":"Osteoclasts: New Insights","volume":"1","author":"Feng","year":"2013","journal-title":"Bone Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Front. Immun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/er.2001-7002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis","volume":"23","author":"Shea","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.amjmed.2006.02.038","article-title":"Randomized controlled trial of calcium in healthy older women","volume":"119","author":"Reid","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","article-title":"Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis","volume":"370","author":"Tang","year":"2007","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF01623348","article-title":"Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients","volume":"4","author":"Chevalley","year":"1994","journal-title":"Osteoporos. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF02556692","article-title":"The effect of fluoride and calcium on spinal bone mineral content: A controlled, prospective (3 years) study","volume":"40","author":"Hansson","year":"1987","journal-title":"Calcif. Tissue Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/jbmr.5650111218","article-title":"Correcting calcium nutritional deficiency prevents spine fractures in elderly women","volume":"11","author":"Recker","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJM199302183280702","article-title":"Effect of calcium supplementation on bone loss in postmenopausal women","volume":"328","author":"Reid","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1359\/jbmr.1998.13.2.168","article-title":"Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women","volume":"13","author":"Riggs","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(05)63013-9","article-title":"Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomised placebo-controlled trial","volume":"365","author":"Grant","year":"2005","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/bmj.330.7498.1003","article-title":"Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care","volume":"330","author":"Porthouse","year":"2005","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.166.8.869","article-title":"Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women","volume":"166","author":"Prince","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00198-015-3386-5","article-title":"Calcium plus vitamin D supplementation and risk of fractures: An updated meta-analysis from the National Osteoporosis Foundation","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2017.21640","article-title":"Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"319","author":"Kahwati","year":"2018","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1210\/jc.2002-020727","article-title":"Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers","volume":"87","author":"Gallagher","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00774-008-0868-y","article-title":"Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls","volume":"26","author":"Moher","year":"2008","journal-title":"J. Bone Miner. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1210\/er.2001-8002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women","volume":"23","author":"Papadimitropoulos","year":"2002","journal-title":"Endocr. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00223-004-0005-4","article-title":"Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis","volume":"76","author":"Richy","year":"2005","journal-title":"Calcif. Tissue Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"d2040","DOI":"10.1136\/bmj.d2040","article-title":"Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women\u2019s Health Initiative limited access dataset and meta-analysis","volume":"342","author":"Bolland","year":"2011","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"b3692","DOI":"10.1136\/bmj.b3692","article-title":"Fall prevention with supplemental and active forms of vitamin D: A meta-analysis of randomised controlled trials","volume":"339","author":"Staehelin","year":"2009","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1447-0756.2006.00386.x","article-title":"Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia","volume":"32","author":"Purwosunu","year":"2006","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1359\/jbmr.2000.15.3.515","article-title":"Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis","volume":"15","author":"Shiraki","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0378-5122(01)00275-4","article-title":"Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women","volume":"41","author":"Ushiroyama","year":"2002","journal-title":"Maturitas"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/archinte.166.12.1256","article-title":"Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials","volume":"166","author":"Cockayne","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00774-008-0008-8","article-title":"Randomized controlled study on the prevention of osteoporotic fractures (OF study): A phase IV clinical study of 15-mg menatetrenone capsules","volume":"27","author":"Inoue","year":"2009","journal-title":"J. Bone Miner. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3390\/nu6051971","article-title":"Vitamin K(2) therapy for postmenopausal osteoporosis","volume":"6","author":"Iwamoto","year":"2014","journal-title":"Nutrients"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF01352009","article-title":"A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women","volume":"53","author":"Meschia","year":"1993","journal-title":"Calcif. Tissue Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0378-5122(01)00243-2","article-title":"Effects of the combined use of calcitonin and 1 alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: A prospective study of long-term and continuous administration with low dose calcitonin","volume":"40","author":"Ushiroyama","year":"2001","journal-title":"Maturitas"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jbmr.1602","article-title":"A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial","volume":"27","author":"Binkley","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjmed.2004.05.019","article-title":"Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study","volume":"117","author":"Ishida","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0169-6009(92)90883-F","article-title":"Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome","volume":"16","author":"Rico","year":"1992","journal-title":"Bone Miner."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00298606","article-title":"Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study","volume":"56","author":"Rico","year":"1995","journal-title":"Calcif. Tissue Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00198-011-1676-0","article-title":"Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: A systematic review and meta-analysis","volume":"23","author":"Homik","year":"2012","journal-title":"Osteoporos. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00024677-200403020-00006","article-title":"Calcitonin therapy in osteoporosis","volume":"3","author":"Alonso","year":"2004","journal-title":"Treat. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00774-004-0556-5","article-title":"Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment","volume":"23","author":"Yoh","year":"2005","journal-title":"J. Bone Miner. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/JCM.S8291","article-title":"Improvement of Quality of Life (QOL) in Osteoporotic Patients by Elcatonin Treatment: A Trial Taking the Participants\u2019 Preference into Account","volume":"3","author":"Yoh","year":"2012","journal-title":"Jpn. Clin. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00774-004-0591-2","article-title":"Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty","volume":"23","author":"Peichl","year":"2005","journal-title":"J. Bone Miner. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","article-title":"Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: A systematic review with network meta-analyses","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40744-016-0030-6","article-title":"Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses","volume":"3","author":"Zhou","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: A meta-analysis","volume":"66","author":"Lin","year":"2012","journal-title":"Int. J Clin. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: Denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semarthrit.2011.03.005","article-title":"Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: A meta-analysis","volume":"41","author":"Hopkins","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) (teriparatide) improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2042098613499790","article-title":"Calcium supplements and cardiovascular risk: 5 years on","volume":"4","author":"Bolland","year":"2013","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jbmr.176","article-title":"Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up","volume":"26","author":"Lewis","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/13697137.2015.1098266","article-title":"Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?","volume":"18","author":"Bolland","year":"2015","journal-title":"Climacteric"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4065\/81.3.353","article-title":"High prevalence of vitamin D inadequacy and implications for health","volume":"81","author":"Holick","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/edrv.22.4.0437","article-title":"Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications","volume":"22","author":"Lips","year":"2001","journal-title":"Endocr Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S8756-3282(01)00645-7","article-title":"Changes in the supporting muscles of the fractured hip in elderly women","volume":"30","author":"Sato","year":"2002","journal-title":"Bone"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1074\/jbc.M702971200","article-title":"Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: Two possible routes for menaquinone-4 accumulation in cerebra of mice","volume":"283","author":"Okano","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(95)90227-9","article-title":"Vitamin, K","volume":"345","author":"Shearer","year":"1995","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/ajcn\/71.5.1201","article-title":"Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women","volume":"71","author":"Booth","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00774-010-0167-2","article-title":"High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment","volume":"28","author":"Shiraki","year":"2010","journal-title":"J. Bone Miner. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00774-008-0034-6","article-title":"Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: A randomized prospective study","volume":"27","author":"Shiraki","year":"2009","journal-title":"J. Bone Miner. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s001980170007","article-title":"Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency","volume":"12","author":"Asakura","year":"2001","journal-title":"Osteoporos. Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0021-9150(97)00087-7","article-title":"Modulation of arterial thrombosis tendency in rats by vitamin K and its side chains","volume":"132","author":"Ronden","year":"1997","journal-title":"Atherosclerosis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ckj\/sfv011","article-title":"Calcitonin, the forgotten hormone: Does it deserve to be forgotten?","volume":"8","author":"Felsenfeld","year":"2015","journal-title":"Clin. Kidney J."},{"key":"ref_80","first-page":"117","article-title":"Calcitonin and calcitonin receptors","volume":"4","author":"Masi","year":"2007","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jbmr.5650090105","article-title":"Histochemical and autoradiographic studies on elcatonin internalization and intracellular movement in osteoclasts","volume":"9","author":"Ikegame","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1523\/JNEUROSCI.20-16-06302.2000","article-title":"Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: Participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord","volume":"20","author":"Ito","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1744-8069-8-42","article-title":"Anti-hyperalgesic effects of calcitonin on neuropathic pain interacting with its peripheral receptors","volume":"8","author":"Ito","year":"2012","journal-title":"Mol. Pain"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1472-8206.2011.00934.x","article-title":"Calcitonin ameliorates enhanced arterial contractility after chronic constriction injury of the sciatic nerve in rats","volume":"26","author":"Yoshimura","year":"2012","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1177\/1060028013509233","article-title":"Salmon calcitonin use and associated cancer risk","volume":"47","author":"Overman","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.joca.2011.11.004","article-title":"Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus","volume":"20","author":"Sondergaard","year":"2012","journal-title":"Osteoarthritis Cartilage"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-015-3339-z","article-title":"Does salmon calcitonin cause cancer? A review and meta-analysis","volume":"27","author":"Wells","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/jbmr.5650100319","article-title":"Relations between histologic indices of bone formation: Implications for the pathogenesis of spinal osteoporosis","volume":"10","author":"Parfitt","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/jbmr.5650110802","article-title":"Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis","volume":"11","author":"Pacifici","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1152\/physrev.00033.2015","article-title":"Estrogens and Androgens in Skeletal Physiology and Pathophysiology","volume":"97","author":"Almeida","year":"2017","journal-title":"Physiol. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2007.07.025","article-title":"Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts","volume":"130","author":"Nakamura","year":"2007","journal-title":"Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1172\/JCI65910","article-title":"Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual","volume":"123","author":"Almeida","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bone.2013.12.005","article-title":"Estrogen receptor alpha in osteocytes regulates trabecular bone formation in female mice","volume":"60","author":"Kondoh","year":"2014","journal-title":"Bone"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1038\/s41598-017-06614-0","article-title":"Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells","volume":"7","author":"Streicher","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: An updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Ann. Int. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jnci\/djp018","article-title":"Prevention of breast cancer in postmenopausal women: Approaches to estimating and reducing risk","volume":"101","author":"Cummings","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_100","first-page":"894","article-title":"Diphosphonates in Paget\u2019s disease","volume":"1","author":"Russell","year":"1974","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","article-title":"Intermittent cyclical etidronate treatment of postmenopausal osteoporosis","volume":"323","author":"Watts","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: The first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/mol.61.5.1255","article-title":"Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite","volume":"61","author":"Lehenkari","year":"2002","journal-title":"Mol. Pharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: Pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos. Int."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40199-017-0167-z","article-title":"New horizons in treatment of osteoporosis","volume":"25","author":"Salari","year":"2017","journal-title":"Daru"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.morpho.2012.08.001","article-title":"Osteomalacia in a patient with Paget\u2019s bone disease treated with long-term etidronate","volume":"96","author":"Hoppe","year":"2012","journal-title":"Morphologie"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal Osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_111","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","article-title":"Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases","volume":"11","author":"Delmas","year":"2008","journal-title":"J. Clin. Densitom."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1345\/aph.1M102","article-title":"Denosumab in osteoporosis and oncology","volume":"43","author":"Burkiewicz","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00198-015-3355-z","article-title":"Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: Case report and literature review","volume":"27","author":"Selga","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_117","first-page":"719","article-title":"Severe Hypocalcemia Following a Single Denosumab Injection","volume":"19","author":"Cernes","year":"2017","journal-title":"IMAJ"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3892\/ol.2017.6121","article-title":"Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review","volume":"14","author":"Yoshimura","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jbmr.5650070110","article-title":"Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone","volume":"7","author":"Hock","year":"1992","journal-title":"J. Bone Miner. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12659\/MSMBR.901142","article-title":"Osteoblast Differentiation at a Glance","volume":"22","author":"Rutkovskiy","year":"2016","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1302\/2046-3758.61.BJR-2016-0085.R1","article-title":"Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation","volume":"6","author":"Sanghani","year":"2017","journal-title":"Bone Joint Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide (rhPTH(1-34)) are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxic. Pathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.yrtph.2017.04.001","article-title":"Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)","volume":"86","author":"Jolette","year":"2017","journal-title":"Regul. Toxic. Pharm."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: molecular regulation of the osteoblast lineage","volume":"13","author":"Long","year":"2011","journal-title":"Nature reviews. Mol. Cell Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1210\/jc.2005-2370","article-title":"Sclerostin and Wnt signaling--the pathway to bone strength","volume":"90","author":"Ott","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2106\/JBJS.G.01183","article-title":"Osteocyte-derived sclerostin inhibits bone formation: Its role in bone morphogenetic protein and Wnt signaling","volume":"90","author":"Krause","year":"2008","journal-title":"J. Bone Joint Surg. Am."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2106\/JBJS.M.01096","article-title":"A review of osteocyte function and the emerging importance of sclerostin","volume":"96","author":"Compton","year":"2014","journal-title":"J. Bone Joint Surg. Am."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bone.2016.11.024","article-title":"Sclerostin expression and functions beyond the osteocyte","volume":"96","author":"Weivoda","year":"2017","journal-title":"Bone"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/dvdy.21054","article-title":"SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development","volume":"236","author":"Deruiter","year":"2007","journal-title":"Dev. Dyn."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Liu, Y., Cao, Y., Zhang, S., Zhang, W., Zhang, B., Tang, Q., Li, Z., and Wu, J. (2018). Romosozumab treatment in postmenopausal women with osteoporosis: A meta-analysis of randomized controlled trials. Climacteric, 1\u20137.","DOI":"10.1080\/13697137.2018.1433655"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1759720X17726744","article-title":"Sclerostin antibodies in osteoporosis: Latest evidence and therapeutic potential","volume":"9","author":"McClung","year":"2017","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Brit. J. Haemat."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11914-017-0376-x","article-title":"Using Osteoporosis Therapies in Combination","volume":"15","author":"McClung","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","article-title":"Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Lou","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide (rhPTH(1-34)) in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"37023","DOI":"10.1074\/jbc.M111.246280","article-title":"Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: Evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts","volume":"286","author":"Furuya","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2017.09.021","article-title":"Effects of single or combination therapy of teriparatide and anti-RANKL monoclonal antibody on bone defect regeneration in mice","volume":"106","author":"Kitaguchi","year":"2018","journal-title":"Bone"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): A randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"16055","DOI":"10.1038\/boneres.2016.55","article-title":"Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women","volume":"5","author":"Nakamura","year":"2017","journal-title":"Bone Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: Differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jbmr.1716","article-title":"Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density","volume":"28","author":"Muschitz","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jcyt.2014.07.009","article-title":"Adipose-derived stem cells alleviate osteoporosis by enhancing osteogenesis and inhibiting adipogenesis in a rabbit model","volume":"16","author":"Ye","year":"2014","journal-title":"Cytotherapy"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/j.1582-4934.2010.01230.x","article-title":"Systemic transplantation of human adipose-derived stem cells stimulates bone repair by promoting osteoblast and osteoclast function","volume":"15","author":"Lee","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1002\/jcp.27833","article-title":"Prospect of mesenchymal stem cells in therapy of osteoporosis: A review","volume":"234","author":"Dolati","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5966\/sctm.2015-0231","article-title":"Systemic Mesenchymal Stromal Cell Transplantation Prevents Functional Bone Loss in a Mouse Model of Age-Related Osteoporosis","volume":"5","author":"Kiernan","year":"2016","journal-title":"Stem cells Transl. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/ten.tea.2012.0047","article-title":"Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice","volume":"19","author":"An","year":"2013","journal-title":"Tissue Engin. Part. A"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/stem.1084","article-title":"Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates","volume":"30","author":"Brown","year":"2012","journal-title":"Stem Cells"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7150\/ijbs.14809","article-title":"Exosomes Secreted by Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Repair Critical-Sized Bone Defects through Enhanced Angiogenesis and Osteogenesis in Osteoporotic Rats","volume":"12","author":"Qi","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Lalu, M.M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B.W., Marshall, J.C., Granton, J., and Stewart, D.J. (2012). Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PloS ONE, 7.","DOI":"10.1371\/journal.pone.0047559"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11914-013-0184-x","article-title":"Stem cell therapy for osteoporosis","volume":"12","author":"Antebi","year":"2014","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13577-013-0078-3","article-title":"Tumorigenesis in cells derived from induced pluripotent stem cells","volume":"27","author":"Nishimori","year":"2014","journal-title":"Hum. Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s11658-016-0013-1","article-title":"Osteoporosis: The current status of mesenchymal stem cell-based therapy","volume":"21","author":"Phetfong","year":"2016","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4155\/tde.13.85","article-title":"Developing siRNA therapies to address osteoporosis","volume":"4","author":"Wang","year":"2013","journal-title":"Ther. Deliv."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2557\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:54:49Z","timestamp":1760187289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":168,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["ijms20102557"],"URL":"https:\/\/doi.org\/10.3390\/ijms20102557","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]}}}